Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Meeting Mic cover art

Meeting Mic

Meeting Mic

Written by: Healio
Listen for free

About this listen
While annual major scientific meetings are the venue to stay up-to-date in your clinical area, it is near impossible to attend all breaking news sessions. Through interviews with experts, Healio's Meeting Mic provides a post-meeting wrap-up of the most important content that listeners can consume on-the-go. Biological Sciences Hygiene & Healthy Living Physical Illness & Disease Science
Episodes
  • Highlights from ESMO 2026
    Nov 17 2026

    In this episode of Meeting Mic, we bring you pearls and perspectives from the European Society for Medical Oncology 2026 Congress.

    In an interview, Susana M. Campos, MD, clinical director of the division of gynecological oncology at Dana-Farber Cancer Institute, provides an overview of highlights in ovarian cancer at the meeting.

    Next, Brian M. Slomovitz, MD, MS, FACOG, director of gynecologic oncology and deputy director of Braman Comprehensive Cancer Center at Mount Sinai Medical Center in Florida, comments on results of the randomized phase 3 KEYNOTE-093 trial.

    Read the full coverage here:

    Chemotherapy-free option may be 'highly desired choice' for endometrial cancer subset

    Slomovitz BM, et al. Abstract LBA12. Presented at: ESMO Congress; Oct. 23-27, 2026; Madrid.

    Sofetabart mipitecan produces 'robust' response in platinum sensitive ovarian cancer

    Kyi C, et al. Abstract 1246RO. Presented at: European Society for Medical Oncology Congress; Oct. 23-27; Madrid.

    Sacituzumab tirumotecan 'new standard of care' for advanced, recurrent endometrial cancer

    Lorusso D, et al. Abstract LBA11. Presented at: European Society for Medical Oncology Congress; Oct. 23-27, 2026; Madrid.

    Digital app 'immensely powerful' in treating insomnia among women with cancer

    Brennan D, et al. Abstract LBA91. Presented at: European Society for Medical Oncology Congress; Oct. 23-27; Madrid.

    Campos reports multiple ties to industry. Slomovitz reports advisory board roles with AADI Bioscience, AstraZeneca, Eisai, Genentech, Gilead Sciences, GSK, Immunogen, Incyte, Merck, Novocure and Seagen. He also is a member of the board of directors for GOG Foundation. Please see the studies for all other authors' relevant financial disclosures.

    Show More Show Less
    13 mins
  • Highlights from AAO 2026
    Nov 2 2026

    In this episode of Meeting Mic, we bring you pearls and perspectives from the American Academy of Ophthalmology annual meeting.

    In an interview, David R.P. Almeida, MD, MBA, PhD, presented the findings of the phase 4 SYNCHRONICITY study of fluocinolone acetonide intravitreal implant 0.18 mg in patients with noninfectious uveitis affecting the posterior segment.

    Ali Tafreshi, CEO of Oku, talks about how they will use a network of more than 10,000 healthcare locations for early disease detection through routine eye exams and how their primary goal is to use this emerging field to address the healthcare cost crisis in the U.S. and globally.

    Next, Jay S. Pepose, MD, PhD, discusses how determining the dominant eye should be one part of monovision planning but not the deciding rule on eye assignment.

    Dilraj Grewal, MD, highlights phase 2 and phase 3 data in age-related macular degeneration. He also discusses subretinal and intravitreal delivery of gene therapy in neovascular AMD and potentially in geographic atrophy.

    And, Sunir J. Garg, MD, FACS, FASRS, discusses what has been learned from phase 3 data on two FDA-approved treatments for geographic atrophy.

    Read the full coverage here:

    Fluocinolone 0.18 mg has sustained improvements in noninfectious posterior segment uveitis

    Oku Digital Health uses eye care to detect diseases earlier

    Monovision planning not always tied to eye dominance

    Continued development may fulfill unmet needs in retina

    Early use of geographic atrophy drugs provides longer protection of vision

    Show More Show Less
    11 mins
  • Highlights from ASRS 2026
    Aug 3 2026

    In this episode of Meeting Mic, we bring you pearls and perspectives from the American Society of Retina Specialists Annual Meeting.

    In an interview, Anat Loewenstein, MD, MHA, of Tel Aviv Medical Center, talks about how Home OCT combined with an AI analysis helped in the early detection of retinal fluid in patients with age-related macular degeneration.

    Next, David Almeida, MD, MBA, PhD, of Erie Retina Research in Pennsylvania, talks about how CG-P5, a topical peptide eye drop, met safety and efficacy endpoints for wet age-related macular degeneration.

    Hasenin Al-khersan, MD, discusses findings from a retrospective study on pegcetacoplan slowing photoreceptor and retinal pigment epithelium loss in patients with geographic atrophy only as well as patients with GA and concurrent wet age-related macular degeneration.

    Sunir J. Garg, MD, FACS, FASRS, discusses findings from a real-world study about suprachoroidal triamcinolone acetonide having a durable effect in patients with chronic cystoid macular edema.

    And, Christina Y. Weng, MD, MBA, FASRS, of Baylor College of Medicine in Houston tells us about her study on systemic statin use reducing the rate of proliferative vitreoretinopathy and reoperation following primary retinal detachment repair by nearly half.

    Read the full coverage here:

    Home OCT with AI comparable to expert graders in AMD

    Loewenstein A. Longitudinal performance of a trend analysis algorithm for home OCT monitoring in neovascular age-related macular degeneration (NVAMD). Presented at: American Society of Retina Specialists annual meeting; July 15-18, 2026; Montreal.

    Peptide eye drop shows fluid, thickness reductions in patients with wet AMD

    Almeida D, et al. Efficacy and safety of a novel topical peptide (CG-P5) for the treatment of neovascular age-related macular degeneration: Phase 1 results. Presented at: American Society of Retina Specialists annual meeting; July 15-18, 2026; Montréal, Canada

    Pegcetacoplan slows photoreceptor, RPE loss in patients with GA and concurrent wet AMD

    Al-khersan H. Assessment of geographic atrophy progression following pegcetacoplan in the real world with and without neovascular age-related macular degeneration. Presented at: American Society of Retina Specialists annual meeting; July 15-18, 2026; Montreal.

    Suprachoroidal triamcinolone shows durable effect in cystoid macular edema

    Garg SJ, et al. Durability and safety of suprachoroidal triamcinolone acetonide in eyes with chronic cystoid macular edema in real-world clinical practice. Presented at: American Society of Retina Specialists annual meeting; July 15-18, 2026; Montreal.

    Study: Statin use halves risk for PVR after retinal detachment surgery

    Weng CY, et al. Statin use and association with proliferative vitreoretinopathy and reoperation risk following retinal detachment surgery. Presented at: American Society of Retina Specialists annual meeting; July 15-18, 2026; Montreal.

    Al-khersan reports consulting for Apellis. Almeida reports being a researcher and consultant for Caregen. Garg reports consulting for Bausch + Lomb. The study was funded by Bausch + Lomb. Loewenstein reports consulting for Notal Vision. Weng reports no relevant financial disclosures.

    Show More Show Less
    17 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet